美股市場個股詳情

FATE Fate Therapeutics

添加自選

4.080
+0.180+4.62%

收盤價 05/10 16:00 (美東)

4.148
+0.068+1.67%

盤後 19:28 (美東)

4.64億總市值-2125市盈率TTM

Fate Therapeutics股票討論區

登錄發表評論

Trytosaveabit

05/09 20:35

Update

$Fate Therapeutics(FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy

Jaguar8

05/09 20:33

$Fate Therapeutics(FATE.US)$
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Meltyy

04/03 11:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Trytosaveabit

03/19 20:45

$Fate Therapeutics(FATE.US)$ Press Release: Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Dow Jones· 1 min ago

Moomoo AI

02/29 19:02

Analysts downgrade revenue estimates for next year and reduce loss estimates. The company's revenue is expected to decline by 92% annually by end of 2024, a shift from historical growth of 47% over the last five years. Fate Therapeutics is expected to lag the wider industry.

US$7.53 - That's What Analysts Think Fate Therapeutics, Inc. (NASDAQ:FATE) Is Worth After These Results

Moomoo AI

2023/12/20 03:53

Fate Therapeutics' P/S ratio aligns with peers due to predicted revenue drop in following years. Given forecasted revenue slide and below par industry growth, future share price gains may be minimal. It's vital to consider the company's future prospects and not just its P/S ratio when deciding to sell stock.